President to Update Investors on Major Strategic Achievements and Plans
for the Remainder of 2007
HERNDON, Va.--(BUSINESS WIRE)--Guardian Technologies International, Inc.
(OTCBB:GDTI), innovators of groundbreaking medical imaging and threat detection
technology with critical and immediate applications for the healthcare and
homeland security markets, will host a live conference call with a simultaneous
webcast, today at 12 noon Eastern to update investors on major strategic
achievements such as the recently extended Cooperative Research and Development
Agreement (CRDA) with the federal Transportation Security Laboratory.
During the conference call, Bill Donovan, President and Chief Operating
Officer of Guardian Technologies, will also discuss the Company’s scheduled image collection initiative of highly-volatile
explosives in Madrid sponsored by TEDAX, the elite Spanish government agency, a
part of the Civil Guard, charged with safeguarding people and property against
terrorist activity.
WHO: Guardian Technologies International
WHAT: Investor Conference Call
WHEN: Today, October 5, 2007, at 12 pm Eastern
HOW: Callers within the United States and Canada may dial 877-209-9922. International callers can dial 612-332-0632.
The impact of Guardian’s industry-first computer
aided detection technologies are immediate and profound for helping to eliminate
human error in both the Homeland Security and the Medical Industry sectors. The
Company’s software solutions can be seamlessly installed
to compliment existing imaging devices, such as baggage scanners and medical
MRI, to scan the contents of any image and immediately identify items of
interest not easily discernable by the human eye.
Airport Security: Guardian’s technology compliments and enhances current-generation
baggage x-ray scanners with the ability to automatically and effectively detect,
locate, and identify explosives and other types of threats.
Disease Identification: Existing
medical imaging devices used in Computer Aided Detection (CAD) are further
improved with Guardian’s auto-diagnostic ability to
detect anomalous tissue (e.g., tumors) and other potential disease states or
conditions.
Technology-Independence: Because
Guardian’s technologies utilize and process the actual
image output generated by the original imaging systems, virtually any existing
or future imaging device can be upgraded with Guardian’s
products, delivering an instant, multi-billion dollar potential customer base
with no competition.
Guardian’s technology and product development
partnerships include a Cooperative Research and Development Agreement (CRDA)
with the U.S. Department of Homeland Security- Science and Technology
Directorate. The Company’s platform and product suite is
protected by a robust patent portfolio. They are also ramping up new
technologies and plan to acquire complimentary technologies to accelerate the
Company’s high-growth business model.
